ClinicalTrials.gg
Not yet recruitingNCT06770426Updated Jan 20, 2025

CompARing Between CO2 Phenylephrine and Phenylephrine Only Treatment in Patients With proGrEssing Cerebral infarctioN

A Phase 3 interventional study of carbogen with or without phenyleprhine and phenylephrine in Acute Ischemic Stroke, sponsored by Yonsei University. Not yet recruiting at 1 site in Korea, Republic of. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2025-01-20.

Sponsored by Yonsei University · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Ischemic Stroke by Yonsei University — 4 open to participants now, 5 under way, 2 of them phase 3. Ischemic Stroke · Yonsei University.

Started
2025
the only one that year
Phase 3
3 of 11
2 open now
Registered
10th of 11
by date

Among the 11 studies in Ischemic Stroke by Yonsei University, this one is the only one that started in 2025, is one of 3 in phase 3, and was the 10th registered.

Ischemic Stroke

2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.

Browse Ischemic Stroke studies →

Open to participants now

4 of the 11 studies in Ischemic Stroke by Yonsei University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Ischemic Stroke by Yonsei University, or all of them as a file.
02

Study summary

Progressing stroke is associated poor functional outcome and neurological deficit.

Currently, no treatment for progressing stroke is recommended on the guideline.

Carbogen is a mixture of 5% CO2 with 95% O2. Carbogen is safe and it is used for the treatment of sudden sensory neural hearing loss or ocular ischemia.

CO2 dilate cerebral arteriole and concentration of CO2 is correlated with cerebral blood flow.

Increased cerebral blood flow following dilation of cerebral arteriole by CO2 might halt and revert progressing stroke.

Induced hypertension is alternative treatment of progressing stroke. Increasing blood pressure also induce cerebral blood flow. Phenylephrine is an α1 agonist, phenylephrine act on peripheral artery and little effect on cerebral artery or heart. Several studies reported that the effectiveness of phenylephrine on progressing stroke.

Therefore, this study will compare the effectiveness of carbogen + phenyleprhine versus phenlyephrine in progressing stroke patients.

03

Conditions studied

  • Acute Ischemic Stroke

Keywords

  • CO2
  • carbogen
  • phenylephrine
  • lacunar infarction
  • progressing stroke
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥20 years
  • Anterior circulation progressing stroke
  • Neurological worsening either 1 point in NIHSS score or MRC grade

Exclusion criteria

Exclusion Criteria:

  • Age under 20 years.
  • Patients with cerebral infarction who are at risk of cerebral edema as determined by the investigator.
  • Patients with Moyamoya disease.
  • Patients with severe cerebrovascular reactivity (CVR) impairment due to cerebral vascular stenosis, making study participation challenging as determined by the investigator.
  • Patients unable to undergo CO2 treatment (e.g., panic disorder, anxiety disorders, or other psychiatric conditions).
  • Patients with to phenylephrine.
  • Patients with persistent bradycardia (heart rate \< 50 bpm).
  • Patients with a history of hemorrhagic stroke or at risk of cerebral hemorrhage.
  • Patients with a pre-stroke modified Rankin Scale (mRS) score ≥ 2, indicating impaired functional independence.
  • Patients ineligible for phenylephrine treatment due to any of the following:

Myocardial infarction or unstable angina within the past 3 months. Cardiac \< 25%. Ventricular arrhythmia. Systolic blood pressure > 200 mmHg. Serum creatinine > 2 mg/dL. Pregnancy.

  • Use of monoamine oxidase (MAO) inhibitors.
  • Patients who do not consent to participate in the study.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Carbogen + phenylephrine group

    Drug: carbogen with or without phenyleprhine

  • Active comparator
    Phenylephrine group

    Drug: phenylephrine

Interventions

  • Drugcarbogen with or without phenyleprhine

    Patients will inhale carbogen gas for 10 minutes and rest for 50 minutes. All patients will recevive phenyleprhine to increase blood pressure. Start phenylephrine with 0.5 mg/hr and titrate upto 3.5 mg/hr or systolic blod pressure 200 mmHg.

  • All patients will recevive phenyleprhine to increase blood pressure. Start phenylephrine with 0.5 mg/hr and titrate upto 3.5 mg/hr or systolic blod pressure 200 mmHg.

06

What researchers measure

Primary outcomes

  1. percent improvement of NIHSS score in each group

    (baseline NIHSS score-post-treatment NIHSS score)/baseline NIHSS score×100

    Time frame: 24 hours

  2. difference of NIHSS score in each group

    baseline NIHSS score-post-treatment NIHSS score

    Time frame: 24 hours

  3. percent improvement of MRC score in each group

    (baseline MRC score-post-treatment MRC score)/baseline MRC score×100

    Time frame: within 24 hours

  4. difference of MRC score in each group

    baseline MRC score-post-treatment MRC score

    Time frame: difference of MRC score in each group

  5. Saftety outcome: Side effect

    Side effect (cerebral hemorrhage, myocardial infarction, Losing consciousness, difficulty breathing, dizziness, fatigue, headache, anxiety, etc)

    Time frame: within 7 days

  6. Saftety outcome: discontinuing patients

    Number of discontinuing patients due to side effects

    Time frame: within 7 days

Secondary outcomes

  1. Comparision between groups by percent improvement of NIHSS score

    (baseline NIHSS score-post-treatment NIHSS score)/baseline NIHSS score×100

    Time frame: 24 hours

  2. Comparision between groups by differnece of NIHSS score

    baseline NIHSS score-post-treatment NIHSS score

    Time frame: 24 hours

  3. Comparision between groups by percent improvement in MRC score

    (baseline MRC score-post-treatment MRC score)/baseline MRC score×100

    Time frame: within 24 hours

  4. Comparision between groups by difference of MRC score

    baseline MRC score-post-treatment MRC score

    Time frame: within 24 hours

  5. Functional independencec

    modifed Rankin score 0 to 2

    Time frame: 3 months after onset

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Feb 2025; primary completion for Sep 2027, 31 months later.

Of 145 non-industry phase 3 interventional studies under Ischemic Stroke, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 62. This study's planned 31 months is close to that.

Counting every sponsor, half of 167 studies reached it within 30 months; a quarter within 19 and three quarters within 52.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 7, 2025
First posted
Jan 13, 2025
StartEst.
Feb 2025
Primary completionEst.
Sep 2027
CompletionEst.
Dec 2027
Last update
Jan 20, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 20, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06770426
Lead sponsor
Yonsei University
Responsible party
Sponsor
First posted
Jan 13, 2025
Start date
Feb 2025 (estimated)
Primary completion
Sep 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Jan 20, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion